mTOR inhibitors everolimus and temsirolimus have been approved for treatment of advanced RCC due to their antitumor activity in clinical trials, although temsirolimus exhibited limited efficacy [243,244,245,246]. This evidence concerns the gene MTOR and renal cell adenocarcinoma.